Bayer hemophilia treatment wins thumbs-up from EU panel
September 21, 2018 at 07:30 AM EDT
Bayer AG's long-acting treatment for hemophilia A has won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily.